Please use this identifier to cite or link to this item: http://repository.kln.ac.lk/handle/123456789/19972
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMettananda, S.-
dc.contributor.authorPathiraja, H.-
dc.contributor.authorPeiris, R.-
dc.contributor.authorWickramarathne, N.-
dc.contributor.authorBandara, D.-
dc.contributor.authorde Silva, U.-
dc.contributor.authorMettananda, C.-
dc.contributor.authorPremawardhena, A.-
dc.date.accessioned2019-02-21T07:04:29Z-
dc.date.available2019-02-21T07:04:29Z-
dc.date.issued2019-
dc.identifier.citationPediatric Blood and Cancer.2019: e27643en_US
dc.identifier.issn1545-5009 (Print)-
dc.identifier.issn1545-5017 (Electronic)-
dc.identifier.urihttp://repository.kln.ac.lk/handle/123456789/19972-
dc.descriptionIndexed in Medlineen_US
dc.description.abstractBACKGROUND: Regular blood transfusion therapy still remains the cornerstone in the management of β-thalassemia. Although recommendations are clear for patients with β-thalassemia major, uniform transfusion guidelines are lacking for patients with hemoglobin E β-thalassemia. In this study, we aim to describe the adequacy, trends, and determinants of blood transfusion therapy in a large cohort of pediatric patients with β-thalassemia major and hemoglobin E β-thalassemia. METHODS/PROCEDURE: This cross-sectional study was performed among all regularly transfused patents with β-thalassemia aged 2 to 18 years attending three large thalassemia centers in Sri Lanka. Data were collected using an interviewer-administered questionnaire, perusal of clinical records, and physical examination of patients by trained doctors. RESULTS: A total of 328 patients (male 47%) were recruited; 83% had β-thalassemia major, whereas 16% had hemoglobin E β-thalassemia. Sixty-one percent of patients had low pretransfusion hemoglobin levels (< 9.0 g/dL) despite receiving high transfusion volumes (> 200 mL/kg/year) by a majority (56%). Median pretransfusion hemoglobin was significantly lower in patients with hemoglobin E β-thalassemia compared with β-thalassemia major (P < 0.001); however, there was no difference in requirement for high transfusion volumes over 200 mL/kg/year in both groups (P = 0.14). Hepatomegaly and splenomegaly were more common in hemoglobin E β-thalassemia and were associated with lower pretransfusion hemoglobin. Transfusion requirements were higher among patients with hepatitis C and in those who are underweight. CONCLUSIONS: Over 60% of regularly transfused patients with β-thalassemia have low pretransfusion hemoglobin levels despite receiving large transfusion volumes. Patients with hemoglobin E β-thalassemia are undertransfused and specific recommendations should be developed to guide transfusions in these patients.en_US
dc.language.isoenen_US
dc.publisherJohn Wileyen_US
dc.subjectHemoglobinopathiesen_US
dc.titleBlood transfusion therapy for β-thalassemia major and hemoglobin E β-thalassemia: adequacy, trends, and determinants in Sri Lanka.en_US
dc.typeArticleen_US
Appears in Collections:Journal/Magazine Articles

Files in This Item:
File Description SizeFormat 
Mettananda_et_al-2019-Pediatric_Blood_&_Cancer.pdf417.91 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.